The FDA approval of ICOTYDE (icotrokinra) in March 2026 created a genuine first in psoriasis treatment: an oral biologic that targets the IL-23 pathway. For years, patients who wanted IL-23 inhibition had exactly one option category — injectable biologics like Skyrizi (risankizumab). Now there is a pill. The obvious question is whether the pill is good enough to compete with what many dermatologists consider the best injectable biologic on the market.
This is not a simple answer. ICOTYDE and Skyrizi target the same pathway but differ in almost every other dimension — delivery, efficacy ceiling, side effect profile, cost structure, and the kind of patient each one serves best. Here is the honest comparison.
Quick Answer: ICOTYDE vs Skyrizi
Skyrizi delivers higher peak skin clearance (~85% PASI 90 vs ~70% for ICOTYDE) but requires subcutaneous injections every 12 weeks. ICOTYDE is a daily oral pill with no needles and no clinic visits, making it the most convenient IL-23 option available. If maximum clearance is your priority and you tolerate injections well, Skyrizi is still the stronger performer. If you want to avoid injections entirely and are willing to accept a modest efficacy trade-off, ICOTYDE is a breakthrough option.
Head-to-Head Comparison Table
| Feature | ICOTYDE (Icotrokinra) | Skyrizi (Risankizumab) |
|---|---|---|
| Drug Class | Oral IL-23 receptor peptide inhibitor | Injectable IL-23p19 monoclonal antibody |
| Manufacturer | Johnson & Johnson / Protagonist Therapeutics | AbbVie |
| FDA Approval | March 2026 | April 2019 |
| Dosing | One tablet daily (with or without food) | 150mg injection at Weeks 0, 4, then every 12 weeks |
| Injections Per Year | 0 | ~5 (after loading) |
| PASI 90 at Week 16 | ~70% | ~85% |
| PASI 100 at Week 16 | ~52% | ~58% |
| Common Side Effects | Nausea (7%), diarrhea (6%), headache (6%) | Injection site reactions (10%), upper respiratory infections (8%) |
| Serious Safety Signals | None in Phase 3 | TB reactivation risk; serious infections (rare) |
| Monitoring | Baseline liver function; no ongoing labs required | TB screening; periodic infection monitoring |
| Annual WAC Cost | ~$15,000–$20,000 (estimated) | ~$18,000–$24,000 |
| Patient Assistance | J&J Care program; $0 copay eligible | AbbVie Complete; $0 copay eligible |
How Each Treatment Works
ICOTYDE: The Oral IL-23 Peptide
ICOTYDE is a constrained cyclic peptide engineered by Protagonist Therapeutics to survive the gastrointestinal tract and bind the IL-23 receptor with high specificity. By blocking IL-23 from activating its receptor on immune cells, ICOTYDE prevents the downstream activation of Th17 cells and the inflammatory cytokines (IL-17A, IL-17F, IL-22) that drive psoriatic plaque formation.
Unlike JAK inhibitors or PDE4 inhibitors, ICOTYDE is a genuine biologic mechanism delivered orally — a technical achievement that took over a decade of peptide engineering. It does not broadly suppress immune function, which contributes to its favorable safety profile in trials.
Skyrizi: The Injectable IL-23 Antibody
Skyrizi is a humanized IgG1 monoclonal antibody that binds specifically to the p19 subunit of IL-23, neutralizing the cytokine before it can engage its receptor. This upstream blockade is highly effective — Skyrizi has consistently demonstrated some of the highest clearance rates in psoriasis clinical trials, including the IMMvent, UltIMMa-1, and UltIMMa-2 studies.
The antibody is administered subcutaneously, with loading doses at Weeks 0 and 4 followed by maintenance injections every 12 weeks. This infrequent dosing schedule is among the most convenient for injectable biologics.
Efficacy: How Well Do They Actually Work?
This is where Skyrizi maintains a meaningful advantage.
In the UltIMMa trials, Skyrizi achieved PASI 90 in approximately 75–85% of patients at Week 16, with responses improving further through Week 52. Long-term extension data shows durable clearance beyond 4 years for the majority of responders. The PASI 100 (complete clearance) rate of ~58% at Week 16 is among the highest of any psoriasis treatment.
ICOTYDE's Phase 3 data showed PASI 90 in approximately 70% of patients at Week 16, with PASI 75 reaching ~85%. These are strong numbers for an oral medication — significantly better than Otezla (~20% PASI 90) and Sotyktu (~40% PASI 90) — but about 15 percentage points below Skyrizi's peak performance.
The practical question is whether the 15-point gap matters to you. For patients with severe, widespread disease who need maximum clearance, that gap is clinically meaningful. For patients with moderate disease or those who prioritize convenience, 70% PASI 90 from a daily pill is a remarkable outcome.
Side Effects and Safety
ICOTYDE Safety Profile
The most common side effects in ICOTYDE trials were gastrointestinal: nausea (7.3%), diarrhea (6.1%), and headache (5.8%). These were predominantly mild and transient, typically resolving within the first 2–4 weeks. No serious infections, malignancies, or cardiovascular events were observed at rates above placebo in Phase 3 data.
Liver enzyme monitoring is recommended at baseline, though no clinically significant elevations were reported. The absence of broad immunosuppression is a meaningful differentiator from JAK inhibitors.
Skyrizi Safety Profile
Skyrizi's most common adverse events include injection site reactions (~10%), upper respiratory tract infections (~8%), and headache (~6%). The drug carries warnings for serious infections, including tuberculosis reactivation, and patients must complete TB screening before initiation.
Long-term safety data spanning 4+ years has been generally reassuring, with no new safety signals emerging. However, as a biologic that requires cold-chain storage and subcutaneous injection, there are inherent logistical considerations.
Cost Analysis: What Will You Actually Pay?
Both medications carry high list prices, as is typical for biologic-class therapies. ICOTYDE's wholesale acquisition cost is estimated at $15,000–$20,000 annually, while Skyrizi runs approximately $18,000–$24,000 per year.
However, list price rarely reflects what patients pay. Both manufacturers offer aggressive patient assistance programs:
- ICOTYDE: J&J's Care program offers $0 copay cards for commercially insured patients and free medication for qualifying uninsured patients.
- Skyrizi: AbbVie Complete offers similar $0 copay support and a free trial program.
Insurance coverage for ICOTYDE is still being established in 2026. Some plans may require step therapy (trying Otezla or Sotyktu first) before approving ICOTYDE. Skyrizi, with 7 years of market presence, generally has broader formulary placement.
The Convenience Factor
This is where ICOTYDE's advantage is unambiguous. Taking a daily pill requires no needles, no refrigeration, no injection training, no clinic visits for administration, and no disposal of sharps. You can travel with ICOTYDE in your carry-on. You can take it at your kitchen table.
Skyrizi's every-12-week schedule is excellent for an injectable — far better than the every-2-week regimens of older biologics — but it still requires subcutaneous injection, cold storage, and the psychological overhead of needles.
For patients with needle phobia, travel-heavy lifestyles, or simply a preference for oral medication, ICOTYDE removes a meaningful barrier to treatment.
Who Should Choose Which?
Choose ICOTYDE If You:
- Have needle phobia or strong preference for oral medication
- Have moderate psoriasis where 70% PASI 90 would represent excellent control
- Travel frequently and want hassle-free treatment
- Are new to biologic-class therapy and want to start with the least invasive option
- Have had injection site reactions or discomfort with previous biologics
Choose Skyrizi If You:
- Have severe, widespread psoriasis requiring maximum clearance
- Are comfortable with infrequent injections (5 per year)
- Prefer not to take a daily medication
- Have GI conditions that might be aggravated by an oral biologic
- Want the treatment with the longest track record and most real-world evidence
The Bottom Line
ICOTYDE and Skyrizi are both excellent psoriasis treatments targeting the same pathway through fundamentally different approaches. Skyrizi offers higher peak efficacy; ICOTYDE offers unmatched convenience. Neither is universally "better" — the right choice depends on your disease severity, lifestyle, and personal priorities.
Use MedSwitcher's Treatment Comparison Tool to see how ICOTYDE and Skyrizi compare for your specific situation, including insurance coverage and out-of-pocket cost estimates. Then bring that information to your dermatologist to make a decision together.